Despite the UN's resolution of ending tuberculosis infection by 2035, it remains a major public health challenge. Tuberculosis used to be the leading cause of death in infectious diseases and became the second after COVID-19 during the pandemic. In 202...
The majority of people in the community who have pulmonary tuberculosis do not report cough, a quarter report no tuberculosis-suggestive symptoms at all, and a quarter of those not reporting any cough have positive sputum smears, suggesting infectiousn...
Wilkins D, Langedijk AC, Lebbink RJ, et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect Dis 2023; 23: 856–66—...
This Personal View discusses the challenges faced, especially by low-income and middle-income countries (LMICs), in responding to the growing burden of bacterial antimicrobial resistance. Many patients in LMICs lack access to effective and affordable t...
Terminology in schistosomiasis is not harmonised, generating misunderstanding in data interpretation and clinical descriptions. This study aimed to achieve consensus on definitions of clinical aspects of schistosomiasis in migrants and returning travel...
All three coprimary endpoints were met in part 2 of the ongoing 2019nCoV-311 study. These data support the development of monovalent and/or bivalent vaccines for the most currently circulating variants, to optimise protection. With no new safety findin...
Lassa fever, a viral haemorrhagic fever endemic to West Africa, remains a substantial health concern in the region. Although its primary mode of transmission is through contact with food and household items contaminated by Mastomys rat urine and faeces...
With the emergence of Omicron variants, which carry several immune escape-related mutations in the spike protein, the effectiveness of COVID-19 prototype vaccines was weakened.1,2 To overcome such weakness, several strategies have been adopted to updat...
The absence of a consensus-based reference standard for urinary tract infection (UTI) research adversely affects the internal and external validity of diagnostic and therapeutic studies. This omission hinders the accumulation of evidence for a disease ...
In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. Th...
In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. Th...
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Plasmodium vivax causes a substantial burden of disease in the Americas, the Horn of Africa, and Asia-Pacific. The parasite forms dormant liver stages (hypnozoites) that reactivate weeks to months after an initial infection causing recurrent episodes o...
Plasmodium vivax causes a substantial burden of disease in the Americas, the Horn of Africa, and Asia-Pacific. The parasite forms dormant liver stages (hypnozoites) that reactivate weeks to months after an initial infection causing recurrent episodes o...
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a monovalent component of the XBB.1.5 variant “to provide be...